Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE
    • Publication Information:
      Publication: New York, N.Y. : Elsevier Science Inc.
      Original Publication: New York Stratton.
    • Subject Terms:
      Sirolimus*/pharmacology ; Mice, Inbred C57BL* ; Liver Cirrhosis*/drug therapy ; Liver Cirrhosis*/pathology ; Disease Models, Animal*; Animals ; Mice ; Liver/drug effects ; Liver/pathology ; Male ; Aspartate Aminotransferases/blood ; Alanine Transaminase/blood ; Nitric Oxide Synthase Type II/metabolism ; Tumor Necrosis Factor-alpha/metabolism ; Creatinine/blood
    • Abstract:
      Background: Liver fibrosis is a chronic inflammatory disease that progresses and has a high mortality rate. This study was performed to investigate the protective effect of rapamycin on experimentally induced chronic liver injury in mice models using both biochemical parameters of liver function enzymes.
      Methods: Twenty-four mice were divided randomly into 4 equal groups: [1] the normal group, n = 6; [2] the liver fibrosis (LF) group, n = 6; [3] the LF with the treatment of rapamycin group, n = 6; [4] the LF with the treatment of silimaryn, n = 6.
      Results: In the group receiving oral administration of rapamycin, aspartate aminotransferase, alanine aminotransferase, urea, and creatinine were found to significantly decrease compared to the liver fibrosis group. Rapamycin, in the orally administered group, demonstrated a statistically significant decrease in the expression of interleukin (IL) 10, IL-1B, inducible nitric oxide synthase, and tumor necrosis factor alpha compared to the liver fibrosis group.
      Conclusions: In this study, we explored the potential therapeutic effects of rapamycin on liver fibrosis in an animal model.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 Elsevier Inc. All rights reserved.)
    • Accession Number:
      W36ZG6FT64 (Sirolimus)
      EC 2.6.1.1 (Aspartate Aminotransferases)
      EC 2.6.1.2 (Alanine Transaminase)
      EC 1.14.13.39 (Nitric Oxide Synthase Type II)
      0 (Tumor Necrosis Factor-alpha)
      AYI8EX34EU (Creatinine)
    • Publication Date:
      Date Created: 20240328 Date Completed: 20240426 Latest Revision: 20240426
    • Publication Date:
      20240427
    • Accession Number:
      10.1016/j.transproceed.2024.03.001
    • Accession Number:
      38548510